Pharmaceuticals, Biotechnology and Life Sciences
Physician executive brings clinical expertise across all phases of development to advance LYR‑210 clinical program and future product pipeline WATERTOWN,…
– Elamipretide in Phase 3 development for primary mitochondrial myopathy – – If option is exercised, Alexion & Stealth will…
– Elamipretide in Phase 3 development for primary mitochondrial myopathy – – If option is exercised, Alexion & Stealth will…
Company Completes Enrollment of Subjects in Trial Designed to Evaluate Safety and Performance of Its Three-Stent System in Standalone Procedure…
Company Completes Enrollment of Subjects in Trial Designed to Evaluate Safety and Performance of Its Three-Stent System in Standalone Procedure…
In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway…
In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway…
DUBLIN–(BUSINESS WIRE)–The “Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)” conference has been added to…
DUBLIN–(BUSINESS WIRE)–The “Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)” conference has been added to…
MGB Biopharma has announced promising phase IIa clinical trial update for oral formulation MGB-BP-3, a potent oral bactericidal antibiotic targeting Clostridium Difficile-Associated Diarrhoea (CDAD), with – as it said in a press release – a completely novel mode of action.